The opinion is based on positive data from the phase 3 Balance study, which showed a significant reduction of triglycerides ...

Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important ...

The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead ...

The EMA's CHMP issues a positive opinion for Tevimbra from BeOne Medicines as a neoadjuvant and adjuvant NSCLC therapy. Read more here.

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

"Tevimbra is already approved in the EU across multiple settings in [non-small cell lung cancer], the most common form of lung cancer, and this positive CHMP opinion expands its potential to help ...

EMA committee recommends marketing approval for Biogen’s Zurzuvae to treat women with postpartum depression: Cambridge, Massachusetts Monday, July 28, 2025, 17:00 Hrs [IST] Biog ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended regulators approve Servier's IDH1/2 inhibitor Voranigo (vorasidenib) as a treatment for ...

Stock of Sarepta Therapeutics Inc. (NASDAQ: SRPT) surged 38.89% in Tuesday pre-market following the U.S. Food and Drug ...

Sarepta Therapeutics (NASDAQ:SRPT) shares dropped sharply premarket on Monday before paring losses as Barclays revised its ...

BeOne Medicines AG (NASDAQ:ONC) saw its stock rise 2.5% in pre-market trading after the European Medicines Agency (EMA) issued a favorable opinion on its cancer drug TEVIMBRA for early-stage lung ...